All Stories

  1. Glibenclamide in patients with poorly controlled type 2 diabetes: a 12-week, prospective, single-center, open-label, dose-escalation study

    Article • Clinical Pharmacology Advances and Applications, April 2014, Taylor & Francis

    Professor viren rambiritch